Boulevard Bio launched with $65 million in initial backing from Deerfield Management and highlighted immune-resetting antibody ambitions in autoimmune kidney disease. The company’s leadership includes Georg Schett, building on a track record positioning immune modulation as a reset mechanism rather than symptom control. The funding comes as investors continue to emphasize differentiation through dosing convenience and mechanism clarity across immune-mediated indications. Boulevard’s launch also fits a broader pattern of early clinical programs emerging from well-capitalized platforms focused on antibody engineering at scale.